Role of c-myc in tamoxifen-induced apoptosis in estrogen-independent breast cancer cells

Journal of the National Cancer Institute

Volumn 88, Issue 5, 1996, Pages 279-284

  Kang, Yuan ^a   Cortina, Robert ^a   Perry, Roger R ^a  

^a EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; ESTROGEN RECEPTOR; MESSENGER RNA; ONCOPROTEIN; TAMOXIFEN;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER GROWTH; DRUG EFFECT; DRUG MECHANISM; ETIOLOGY; GENE EXPRESSION; HUMAN; HUMAN CELL; ONCOGENE C MYC; PROTEIN EXPRESSION;

ANTINEOPLASTIC AGENTS, HORMONAL; APOPTOSIS; BASE SEQUENCE; BREAST NEOPLASMS; ESTROGEN ANTAGONISTS; FEMALE; HUMANS; MOLECULAR SEQUENCE DATA; OLIGONUCLEOTIDES, ANTISENSE; PROTO-ONCOGENE PROTEINS C-MYC; RECEPTORS, ESTROGEN; RNA, MESSENGER; TAMOXIFEN; TUMOR CELLS, CULTURED;

EID: 0029958760     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/88.5.279     Document Type: Article

References (33)

1. Reddel RR, Murphy LC, Hall RE, Sutherland RL. Differential sensitivity of human breast cancer cell lines to the growth-inhibitory effects of tamoxifen. Cancer Res 1985;45:1525-31.
2. Jaiyesimi IA, Buzdar AU, Decker DA, Hortobagyi GN. Use of tamoxifen for breast cancer: twenty-eight years later [see comment citation in Medline]. J Clin Oncol 1995;13: 513-29.
3. Perry RR, Kang Y, Greaves B. Effects of tamoxifen on growth and apoptosis of estrogen-dependent and -independent human breast cancer cells. Ann Surg Oncol 1995;2:238-45.
4. Watson PH, Pon RT, Shiu RP. Inhibition of c-myc expression by phosphorothioate antisense oligonucleotide identifies a critical role for c-myc in the growth of human breast cancer. Cancer Res 1991;51:3996-4000.
5. Evan GI, Wyllie AH, Gilbert CS, Littlewood TD, Land H, Brooks M, et al. Introduction of apoptosis in fibroblasts by c-myc protein. Cell 1992;59:119-28.
6. Dubik D, Shiu RP. Transcriptional regulation of c-myc oncogene expression by estrogen in hormone-responsive human breast cancer cells. J Biol Chem 1988;263:12705-8.
7. Dubik D, Dembinski TC, Shiu RP. Stimulation of c-myc oncogene expression associated with estrogen-induced proliferation of human breast cancer cells. Cancer Res 1987;47:6517-21.
8. Dubik D, Shiu RP, Mechanism of estrogen activation of c-myc oncogene expression. Oncogene 1992;7:1587-94.
9. Wosikowski K, Kung W, Hasmann M. Loser R, Eppenberger U. Inhibition of growth-factor-activation proliferation by anti-estrogens and effects on early gene expression of MCF-7 cells, Int J Cancer 1993;53:290-7.
10. 3 analogues and tamoxifen. Cancer Res 1994;54:5711-7.
11. Lien EA, Solheim E, Lea OA, Lundgren S, Kvinnsland S, Ueland PM. Distribution of 4-hydroxy-N-desmethyltamoxifen and other tamoxifen metabolites in human biological fluids during tamoxifen treatment. Cancer Res 1989;49:2175-83.
12. Reddel RR, Murphy LC, Sutherland RL. Factors affecting the sensitivity of T-47D human breast cancer cells to tamoxifen. Cancer Res 1984;44:2398-405.
13. Kang Y. Perry RR. Effect of alpha-interferon on P-glycoprotein expression and function and on verapamil modulation of doxorubicin resistance. Cancer Res 1994;54:2952-8.
14. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976;72:248-54.
15. Giles RV, Spiller DG, Tidd DM, Detection of ribonuclease H-generated mRNA fragments in human leukemia cells following reversible membrane permeabilization in the presence of antisense oligodeoxynucleotides. Antisense Res Dev 1995;5:23-31.
16. Bardon S, Vignon F, Montcourrier P, Rochefort H. Steroid receptor-mediated cytotoxicity of an antiestrogen and an antiprogestin in breast cancer cells. Cancer Res 1987;47: 1441-8.
17. Warri AM. Huovinen RL, Laine AM, Martikainen PM, Harkonen PL. Apoptosis in toremifene-induced growth inhibition of human breast cancer cells in vivo and in vitro. J Natl Cancer Inst 1993;85:1412-8.
18. Osborne CK, Boldt DH, Estrada P. Human breast cancer cell cycle synchronization by estrogens and antiestrogens in culture. Cancer Res 1984;44:1433-9.
19. Hug V, Hortobagyi GN, Drewinko B, Finders M. Tamoxifen-citrate counteracts the antitumor effects of cytotoxic drugs in vitro. J Clin Oncol 1985;3:1672-7.
20. Katzenellenbogen BS, Norman MJ, Eckert RL, Peltz SW, Mangel WF. Bioactivities. estrogen receptor interactions, and plasminogen activator-inducing activities of tamoxifen and hydroxy-tamoxifen isomers in MCF-7 human breast cancer cells. Cancer Res 1984;44:112-9.
21. Pratt SE, Pollak MN. Estrogen and antiestrogen modulation of MCF7 human breast cancer cell proliferation is associated with specific alterations in accumulation of insulin-like growth factor-binding proteins in conditioned media. Cancer Res 1993;53:5193-8.
22. Rempel SA, Johnston RN. Steroid-induced cell proliferation in vivo is associated with increased c-myc proto-oncogene transcript abundance. Development 1988;104:87-95.
23. Shiu RP. Watson PH. Dubik D. C-myc oncogene expression in estrogen-dependent and -independent breast cancer. Clin Chem 1993;39:353-5.
24. Leder A. Pattengale PK, Kuo A, Stewart TA, Leder P. Consequences of widespread deregulation of the c-myc gene in transgenic mice: multiple neoplasms and normal development. Cell 1986;45:485-95.
25. Cherney BW, Bhatia K, Tosato G. A role for deregulated c-Myc expression in apoptosis of Epstein-Barr virus-immortalized B cells. Proc Natl Acad Sci USA 1994;91:12967-71.
26. Jeng MH, ten Dijke P, Iwata KK, Jordan VC. Regulation of the levels of three transforming growth factor beta mRNAs by estrogen and their effects on the proliferation of human breast cancer cells. Mol Cell Endocrinol 1993;97:115-23.
27. Noguchi S, Motomura K, Inaji H, Imaoka S, Koyama H. Down-regulation of transforming growth factor-alpha by tamoxifen in human breast cancer [see comment citation in Medline]. Cancer 1993;72:131-6.
28. Alexandrow MG, Kawabata M, Aakre M, Moses HL. Overexpression of the c-Myc oncoprotein blocks the growth-inhibitory response but is required for the mitogenic effects of transforming growth factor beta I. Proc Natl Acad Sci U S A 1995;92:3239-43.
29. Wang TT, Phang JM. Effects of estrogen on apoptotic pathways in human breast cancer cell line MCF-7. Cancer Res 1995;55:2487-9.
30. Vancutsem PM, Lazarus P, Williams GM. Frequent and specific mutations of the rat p53 gene in hepatocarcinomas induced by tamoxifen. Cancer Res 1994;54:3864-7.
31. Fanidi A, Harrington EA, Evan Gl. Cooperative interaction between c-myc and bcl-2 proto-oncogenes. Nature 1992;359:554-6.
32. Wagner AJ, Kokontis JM, Hay N. Mycmediated apoptosis requires wild-type p53 in a manner independent of cell cycle arrest and the ability of p53 to induce p21waf1/cip1. Genes Dev 1994;8:2817-30.
33. Amati B, Brooks MW, Levy N, Littlewood TD, Evan GI, Land H. Oncogenic activity of the c-Myc protein requires dimerization with Max. Cell 1993;72:233-45.